IP Library Granted Patent US 10,463,742
Granted Patent B2
US 10,463,742 · App. 16/387,407 · Granted Nov 5, 2019

Topical tetracycline compositions

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,463,742
App. No.
16/387,407
Granted
Nov 5, 2019
Kind
B2
Abstract

A topical therapeutic hydrophobic breakable composition includes a carrier comprising (a) about 60% to about 99% by weight of at least one hydrophobic oil; (b) at least one viscosity-modifying agents selected from the group consisting of a fatty alcohol, a fatty acid and a wax; and (c) a tetracycline antibiotic, characterized in that at least part of the tetracycline antibiotic is suspended in the composition; the viscosity of the composition is at least about 30% higher than the viscosity of the carrier without the tetracycline antibiotic; and is higher than the viscosity or the hydrophobic oil and the tetracycline antibiotic without the viscosity modifying agents. The tetracycline is chemically stable in the composition for at least six months; wherein more than about 90% of the tetracycline has not broken down. The composition is packaged as a breakable foam that breaks easily upon application of shear force.

Claims (76)

1. A waterless foam composition comprising:

a minocycline;

a retinoid; and

a foamable carrier, the carrier comprising:

a) at least one hydrophobic oil; and

b) an agent comprising (i) at least one fatty alcohol and at least one wax; (ii) at least one fatty acid and at least one wax; (iii) at least one fatty alcohol, at least one fatty acid, and at least one wax; (iv) a wax comprising a hydrogenated oil; or (v) a combination of two or more waxes;

wherein the composition does not contain one or more minocycline incompatible substance selected from the group consisting of dimethyl sulfoxide (DMSO), dimethylformamide (DMF), acetonitrile, acetone, methyl ethyl ketone, 1,4-dioxane, tetrahydrofuran (THF), N-methylpyrrolidone, pyridine, piperidine, N-methyl-2-pyrrolidone and 1-methyl-2-pyrrolidinone), azone (1-dodecylazacycloheptan-2-one), dimethyl isosorbide, glycerin, ethanol, propylene glycol, butylene glycol, PEG 200, hexylene glycol, PEG 400, diethylene glycol monoethyl ether, pomegranate seed oil, isostearic acid, and ethylcellulose;

wherein the composition does not contain a surfactant;

and wherein the composition does not contain a polyol.

2. The composition of claim 1 , wherein the at least one hydrophobic oil comprises a mineral oil, a cocoglyceride, a silicone oil, a liquid paraffin, a caprylic/capric triglyceride, a coconut oil, a soybean oil, a cyclomethicone, disopropyl adipate isododecane, cetearyl octanoate, a gelled mineral oil, isopropyl myristate, PPG 15 stearyl ether, octyl dodecanol, a petrolatum, a calendula oil, a grape seed oil, an almond oil, a jojoba oil, an avocado oil, a peanut oil, a wheat germ oil, or a mixture of any two or more thereof.

3. The composition of claim 1 , wherein at least one or both of the fatty alcohol or the fatty acid has at least 12 carbon atoms in its carbon backbone.

4. The composition of claim 1 , wherein the agent comprises at least one fatty alcohol, at least one fatty acid, and at least one wax, wherein the at least one wax comprises a beeswax, a hydrogenated oil, or both.

5. The composition of claim 1 , wherein the composition contains (1) less than 0.4% by weight of a protic solvent, a polar aprotic solvent, and a silicone thickening agent or (2) less than 0.4% by weight of a polymeric gelling agent, a short chain alcohol, and a silicone thickening agent.

6. The composition of claim 1 , wherein the foamable carrier comprises:

a) 45% to 55% by weight of a soybean oil;

b) 21.2% to 26% by weight of a coconut oil;

c) 4.5% to 5.5% by weight of a cyclomethicone;

d) 0.85% to 4.8% by weight of a light mineral oil;

e) 3.2% to 3.9% by weight of cetostearyl alcohol;

f) 2.7% to 3.3% by weight of stearic acid;

g) 2.3% to 2.8% by weight of myristyl alcohol;

h) hydrogenated castor oil;

i) beeswax;

j) 1.4% to 1.7% by weight of stearyl alcohol; and

k) 1% to 1.2% by weight of behenyl alcohol.

7. The composition of claim 6 , wherein hydrogenated castor oil is present at about 0.1% to about 1% of the composition or at about 1% to about 5% of the composition.

8. The composition of claim 6 , wherein beeswax is present at about 1% to about 10% of the composition.

9. The composition of claim 1 , wherein the minocycline is present at about 1% to about 10% of the composition.

10. The composition of claim 1 , wherein the minocycline is present at about 3% of the composition.

11. The composition of claim 1 , wherein the retinoid is adapalene.

12. The composition of claim 1 , wherein the composition is free of or comprises less than 10% petrolatum by weight of the composition.

13. The composition of claim 1 , wherein the at least one hydrophobic oil is about 60% to about 99% by weight of the composition.

14. The composition of claim 1 , wherein the foam composition is produced with a liquefied or compressed gas propellant.

15. The composition of claim 1 , comprising a hydrocarbon oil, an ester oil, an ester of a dicarboxylic acid, a triglyceride oil, an unsaturated or polyunsaturated oil, an essential oil, a canola oil, a castor oil, a corn oil, a cotton oil, a cottonseed oil, glycerol, an olive oil, a palm oil, a dimethicone, a fatty acid-modified silicone oil, or a mixture of any two or more thereof.

16. A method of treating or alleviating the symptoms of a dermatological disorder, comprising: applying to a target area the composition of claim 1 .

17. The method of claim 16 , wherein the composition is administered at least once daily.

18. The method of claim 16 , wherein the composition is administered at least once daily and the minocycline is present at about 3% of the composition.

19. The method of claim 16 , wherein the disorder is acne.

20. A waterless composition comprising:

a carrier;

a retinoid; and

1% to 10% by weight of the composition of a minocycline,

wherein the carrier comprises:

a) at least one hydrophobic oil; and

b) an agent comprising (i) at least one fatty alcohol and at least one wax; (ii) at least one fatty acid and at least one wax; (iii) at least one fatty alcohol, at least one fatty acid, and at least one wax; (iv) a wax comprising a hydrogenated oil; or (v) a combination of two or more waxes;

wherein the composition does not contain a surfactant;

wherein the composition does not contain a polyol.

21. The composition of claim 20 , wherein the minocycline is minocycline hydrochloride and is present at an amount of about 3% by weight of the composition.

22. The composition of claim 20 , wherein the agent comprises at least one fatty alcohol, at least one fatty acid, and at least one wax.

23. The composition of claim 20 , wherein the composition is a foam composition, and wherein the foam composition is produced upon addition of a liquefied or compressed gas propellant to the carrier.

24. The composition of claim 20 , wherein the retinoid is adapalene.

25. The composition of claim 20 , wherein the carrier comprises:

a) 45% to 55% by weight of a soybean oil;

b) 21.2% to 26% by weight of a coconut oil;

c) 4.5% to 5.5% by weight of a cyclomethicone;

d) 0.85% to 4.8% by weight of a light mineral oil;

e) 3.2% to 3.9% by weight of cetostearyl alcohol;

f) 2.7% to 3.3% by weight of stearic acid;

g) 2.3% to 2.8% by weight of myristyl alcohol;

h) hydrogenated castor oil;

i) beeswax;

j) 1.4% to 1.7% by weight of stearyl alcohol; and

k) 1% to 1.2% by weight of behenyl alcohol.

26. The composition of claim 25 , wherein hydrogenated castor oil is present at about 0.1% to about 1% of the composition or at about 1% to about 5% of the composition.

27. The composition of claim 25 , wherein beeswax is present at about 1% to about 10% of the composition.

28. A method of treating or alleviating the symptoms of a dermatological disorder, comprising: applying to a target area the composition of claim 20 .

29. The method of claim 28 , wherein the disorder is acne.

30. A waterless composition comprising:

a carrier;

a retinoid; and

1% to 10% by weight of the composition of a tetracycline antibiotic,

wherein the carrier comprises:

a) at least one hydrophobic oil; and

b) an agent comprising (i) at least one fatty alcohol and at least one wax; (ii) at least one fatty acid and at least one wax; (iii) at least one fatty alcohol, at least one fatty acid, and at least one wax; (iv) a wax comprising a hydrogenated oil; or (v) a combination of two or more waxes;

wherein the composition does not contain a surfactant;

wherein the composition does not contain a polyol.

Assignments (11)
SECURITY INTEREST Recorded Dec 28, 2023
From: JOURNEY MEDICAL CORPORATION; JG PHARMA, INC.
To: SWK FUNDING LLC
Reel/Frame 066157/0079 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 1, 2022
From: VYNE THERAPEUTICS INC.; VYNE PHARMACEUTICALS INC.
To: JOURNEY MEDICAL CORPORATION
Reel/Frame 058925/0568 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 22, 2021
From: VYNE THERAPEUTICS INC.
To: VYNE PHARMACEUTICALS INC.
Reel/Frame 058463/0208 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE PHARMACEUTICALS LTD. (F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0138 →
RELEASE OF SECURITY INTEREST Recorded Sep 20, 2021
From: PERCEPTIVE CREDIT HOLDINGS II, LP
To: VYNE THERAPEUTICS INC. (F/K/A MENLO THERAPEUTICS INC. AND SUCCESSOR-IN-INTEREST TO VYNE PHARMACEUTICALS LTD., F/K/A FOAMIX PHARMACEUTICALS LTD.)
Reel/Frame 057544/0708 →
PATENT SECURITY AGREEMENT Recorded Feb 17, 2021
From: VYNE THERAPEUTICS INC.
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 055326/0009 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2021
From: VYNE PHARMACEUTICALS LTD.
To: VYNE THERAPEUTICS INC.
Reel/Frame 055215/0298 →
CHANGE OF NAME Recorded Nov 4, 2020
From: FOAMIX PHARMACEUTICALS LTD.
To: VYNE PHARMACEUTICALS LTD.
Reel/Frame 054306/0387 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 3, 2019
From: TAMARKIN, DOV; GAZAL, ELANA; PAPIASHVILI, IRAKLIY; HAZOT, YOHAN; SCHUZ, DAVID; KEYNAN, RITA
To: FOAMIX LTD.
Reel/Frame 050614/0277 →
CHANGE OF NAME Recorded Oct 3, 2019
From: FOAMIX, LTD
To: FOAMIX PHARMACEUTICALS, LTD.
Reel/Frame 050614/0557 →
PATENT SECURITY AGREEMENT Recorded Jul 30, 2019
From: FOAMIX PHARMACEUTICALS LTD
To: PERCEPTIVE CREDIT HOLDINGS II, LP
Reel/Frame 049912/0045 →